211 related articles for article (PubMed ID: 2525004)
1. [Combination therapy with medroxyprogesterone acetate and tegafur in tamoxifen- and adriamycin-resistant advanced breast cancers].
Wada T; Matunami N; Houjou T; Morikawa E; Mori N; Nakano K; Aizawa M; Kurooka K; Kadota K; Yamato M
Gan To Kagaku Ryoho; 1989 May; 16(5):2087-92. PubMed ID: 2525004
[TBL] [Abstract][Full Text] [Related]
2. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
Nomura Y; Tashiro H; Hisamatsu K; Toi M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
[TBL] [Abstract][Full Text] [Related]
3. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women.
Mouridsen HT; Ellemann K; Mattsson W; Palshof T; Daehnfeldt JL; Rose C
Cancer Treat Rep; 1979 Feb; 63(2):171-5. PubMed ID: 376131
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
Yoshida M; Murai H; Miura S
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
[TBL] [Abstract][Full Text] [Related]
6. [Results of tamoxifen-medroxyprogesterone acetate sequential therapy in 22 patients with recurrent breast cancer].
Noguchi S; Yamamoto H; Inaii H; Koyama H
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3555-8. PubMed ID: 2530936
[TBL] [Abstract][Full Text] [Related]
7. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.
Lorenz I; Mechl Z
Neoplasma; 1985; 32(1):119-24. PubMed ID: 3157070
[TBL] [Abstract][Full Text] [Related]
8. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
Mauriac L; Durand M; Bonichon F; Chauvergne J
Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
[TBL] [Abstract][Full Text] [Related]
9. [A case of disseminated breast cancer successfully treated with medroxyprogesterone acetate].
Tsumura I; Okamura Y; Takatsuka Y; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1509-12. PubMed ID: 2143889
[TBL] [Abstract][Full Text] [Related]
10. [Hormone therapy of breast cancer-its role in the treatment of breast cancer].
Koyama H; Shiba E
Gan No Rinsho; 1985 Jul; 31(9 Suppl):1177-81. PubMed ID: 2932568
[TBL] [Abstract][Full Text] [Related]
11. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
[TBL] [Abstract][Full Text] [Related]
12. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
[TBL] [Abstract][Full Text] [Related]
13. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
14. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
Mallmann P; Dietrich K; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
[TBL] [Abstract][Full Text] [Related]
15. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
[TBL] [Abstract][Full Text] [Related]
16. [Combination chemotherapy using low-dose epirubicin and vindesine in patients with metastatic breast cancer].
Takatsuka Y; Nakayama H; Kawahara T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):667-71. PubMed ID: 2965547
[TBL] [Abstract][Full Text] [Related]
17. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
[TBL] [Abstract][Full Text] [Related]
18. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
19. [A combined chemo-endocrine therapy with tegafur, adriamycin, methotrexate and tamoxifen for advanced renal cell carcinoma].
Wada T; Morikawa E; Yasutomi M; Takagi H; Aizawa M; Abe T; Wada A
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1652-6. PubMed ID: 2230447
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of estramustine phosphate in the treatment of patients with advanced breast cancers].
Wada T; Morikawa E; Houjou T; Kadota K; Mori N; Matsunami N; Watatani M; Yasutomi M
Gan To Kagaku Ryoho; 1990 Sep; 17(9):1901-4. PubMed ID: 2393306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
